Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Non Operating Income: 2016-2025

Historic Non Operating Income for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to -$2.1 million.

  • Heron Therapeutics' Non Operating Income fell 428.97% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 136.64%. This contributed to the annual value of -$2.1 million for FY2024, which is 466.43% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Non Operating Income is -$2.1 million, which was down 177.28% from -$744,000 recorded in Q2 2025.
  • Heron Therapeutics' Non Operating Income's 5-year high stood at $1.6 million during Q1 2024, with a 5-year trough of -$6.9 million in Q2 2022.
  • Its 3-year average for Non Operating Income is -$481,800, with a median of -$450,000 in 2024.
  • As far as peak fluctuations go, Heron Therapeutics' Non Operating Income crashed by 1,156.59% in 2022, and later surged by 455.25% in 2024.
  • Over the past 5 years, Heron Therapeutics' Non Operating Income (Quarterly) stood at -$1.1 million in 2021, then soared by 143.82% to $486,000 in 2022, then slumped by 203.85% to -$79,000 in 2023, then slumped by 393.67% to -$510,000 in 2024, then tumbled by 428.97% to -$2.1 million in 2025.
  • Its Non Operating Income was -$2.1 million in Q3 2025, compared to -$744,000 in Q2 2025 and -$519,000 in Q1 2025.